Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$27,000.00

Enhancing Oncolytic Virus Therapeutics: A Viral Cloaking Strategy for Extended Circulation and Improved Efficacy

FY 2024-25

Summary
Oncolytic viruses (OVs) are infectious viruses that have been strategically weakened to allow for infection of cancer cells without harming healthy cells. OVs selectivity is attributed to weaker antiviral defences of cancer cells, permitting viral infection. While OVs are a rapidly growing therapeutic in the clinic for cancer treatment, there remain drawbacks to their widespread use, such as rapid clearance by one's immune system. To address inherent limitations and advance current cancer therapeutics, we are proposing the design of new, modified OVs using a chemical cloaking strategy. Areversible chemical cloak will be designed such that the virus can be masked in the presence of healthy cells but will shed its cloak in the tumour microenvironment (TME). The TME has an acidic environment that will allow for the selective release of the viral mask and infection of cancer cells. Using this novel chemical approach, we can extend OV circulation time and maintain potency on par with unmodified OVs.Previous literature has shown the capacity for OVs to be masked from immune detection using large chemical groups. We intend to use these groups appended to reversible, reactive species termed reversible covalent electrophiles. The electrophiles facilitate the binding interaction between the masking agent and virus surface, preventing viral entry and infection. The reversibility of the electrophile permits the selective release of the OV in the TME's acidic environment. The proposed approach is anticipated to give the benefits of stability, improved target specificity, and potency without compromising cell infectivity. The reversibility of the masking agent is a novel strategy in cancer immunotherapy that has the potential to inaugurate a new field of masked therapeutic drugs.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
529660
Name
Kalra Ishita
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Enhancing Oncolytic Virus Therapeutics: A Viral Cloaking Strategy for Extended Circulation and Improved Efficacy
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Immunology; Chemical Biology; Virology
Abstract
Oncolytic viruses (OVs) are infectious viruses that have been strategically weakened to allow for infection of cancer cells without harming healthy cells. OVs selectivity is attributed to weaker antiviral defences of cancer cells, permitting viral infection. While OVs are a rapidly growing therapeutic in the clinic for cancer treatment, there remain drawbacks to their widespread use, such as rapid clearance by one's immune system. To address inherent limitations and advance current cancer therapeutics, we are proposing the design of new, modified OVs using a chemical cloaking strategy. Areversible chemical cloak will be designed such that the virus can be masked in the presence of healthy cells but will shed its cloak in the tumour microenvironment (TME). The TME has an acidic environment that will allow for the selective release of the viral mask and infection of cancer cells. Using this novel chemical approach, we can extend OV circulation time and maintain potency on par with unmodified OVs.Previous literature has shown the capacity for OVs to be masked from immune detection using large chemical groups. We intend to use these groups appended to reversible, reactive species termed reversible covalent electrophiles. The electrophiles facilitate the binding interaction between the masking agent and virus surface, preventing viral entry and infection. The reversibility of the electrophile permits the selective release of the OV in the TME's acidic environment. The proposed approach is anticipated to give the benefits of stability, improved target specificity, and potency without compromising cell infectivity. The reversibility of the masking agent is a novel strategy in cancer immunotherapy that has the potential to inaugurate a new field of masked therapeutic drugs.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kalra, Ishita
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~